ClinicalTrials.gg
RecruitingNCT07158905TAURUS-1980Updated Aug 21, 2026

AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

A Phase 1 interventional study of AV-1980R 20 µg and AV-1980R 60 µg in Alzheimer Disease and Preclinical Alzheimer's Disease, sponsored by Institute for Molecular Medicine. Recruiting at 6 sites in United States. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Institute for Molecular Medicine · Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
65 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Planned enrollment
985th of 1,610
48 · median 73
Started
2026
with 91 others
Phase 1
304 of 1,941
31 open now
Primary completion
2029-06
later than 371 of 443 live
Registered
1,838th of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 985th largest by planned enrollment of the 1,610 interventional ones that give a count, is one of 92 that started in 2026, is one of 304 in phase 1, reaches primary completion later than 371 of the 443 other live ones, and was the 1,838th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 65 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study evaluating the safety, tolerability, and immunogenicity of AV-1980R, an investigational vaccine targeting pathological tau, in participants with preclinical Alzheimer's disease. Up to 48 cognitively unimpaired adults aged 65 to 80 years with biomarker evidence of preclinical Alzheimer's disease will be enrolled into three ascending-dose cohorts.

Read the detailed description

This study will evaluate AV-1980R, a MultiTEP-based active immunotherapy formulated with Advax-CpG55.2 adjuvant, in participants with preclinical Alzheimer's disease. Up to 48 participants aged 65 to 80 years will be randomized in a 3:1 ratio to receive AV-1980R or placebo in three ascending-dose cohorts of 20 µg, 60 µg, and 180 µg.

Participants will receive three intramuscular injections at Weeks 0, 4, and 38, with follow-up visits through Week 58. The primary objective is to evaluate safety and tolerability. Secondary objectives include evaluation of anti-tau antibody responses and T-cell responses. Exploratory assessments include plasma Alzheimer's disease biomarkers, tau PET imaging, immune-response characteristics, and cognitive measures.

03

Conditions studied

  • Alzheimer Disease
  • Preclinical Alzheimer's Disease

Keywords

  • Tau protein
  • Immunotherapy
  • Vaccine
  • Preclinical Alzheimer's Disease
  • Alzheimer's Disease
  • secondary prevention
  • Neurodegeneration
  • Preventive Alzheimer's
04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or or surgically sterile female, 65 to 80 years of age, inclusive.

Cognitively unimpaired participant with preclinical Alzheimer's disease who meets all of the following:

Clinical Dementia Rating global score of 0 at Screening. score ≥26, with education adjustment at Screening.

Plasma p-tau217/Aβ42 ratio ≥0.00738 measured using Lumipulse (Fujirebio). A prior positive result obtained within 12 months before Screening may be accepted but must be confirmed by the central laboratory.

Sight and hearing, including use of a hearing aid, sufficient to comply with study procedures.

Stable concomitant medications. Participants receiving fluctuating medication or treatment may be considered if the underlying condition is controlled.

Signed before any study-related procedure. Ability, in the Investigator's opinion, to understand the study and comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

Screening MRI showing any of the following:

More than one noncortical lacunar infarct greater than 1.5 cm. Any territorial infarct greater than 1.5 cm. Combined microbleeds and areas of hemosiderosis greater than 5, or disseminated leptomeningeal hemosiderosis.

Any other significant cerebral abnormality, including ARIA-E. to MRI, including non-MRI-safe implanted metallic devices or claustrophobia.

Serious illness requiring systemic treatment or hospitalization within 4 weeks before study entry.

Clinically relevant cardiovascular, respiratory, gastrointestinal, endocrine, immunologic, hematologic, systemic disease, or major surgery that could interfere with participation or follow-up.

Insulin-dependent diabetes. Clinically relevant cardiac arrhythmia, palpitation, conduction abnormality, prolonged , or bundle branch block.

Pre-existing disease. C-SSRS score of 3 or higher. History of seizure disorder, except permitted stable use of certain antiepileptic medications for chronic pain.

Any medical, psychological, or social condition that could interfere with participation, compliance, or participant safety.

Participation in another drug study or use of an investigational drug within 30 days or 5 half-lives, whichever is longer, before dosing.

Prior tau or amyloid-beta immunotherapy within 1 year before Screening. Use of specified immunomodulatory or growth-stimulating treatments within 30 days before study entry.

Chronic use for more than 3 months of warfarin, other coumarin derivatives, anticoagulants, or an antiplatelet agent such as clopidogrel.

Parenteral immunoglobulin preparations, blood products, or plasma derivatives. History of severe local or systemic vaccination reactions or significant allergic reactions.

Clinically significant laboratory abnormalities at Screening, including or AST greater than 1.5 times the .

Positive testing for -1 or HIV-2, surface antigen, or .

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    AV-1980R 20 µg Arm

    Participants receive 20 µg of AV-1980R formulated with Advax-CpG55.2 by intramuscular injection at Weeks 0, 4, and 38.

    Biological: AV-1980R 20 µg

  • Experimental
    AV-1980R 60 µg Arm

    Participants receive 60 µg of AV-1980R formulated with Advax-CpG55.2 by intramuscular injection at Weeks 0, 4, and 38.

    Biological: AV-1980R 60 µg

  • Experimental
    AV-1980R 180 µg Arm

    Participants receive 180 µg of AV-1980R formulated with Advax-CpG55.2 by intramuscular injection at Weeks 0, 4, and 38.

    Biological: AV-1980R 180 µg

  • Placebo comparator
    Placebo Arm

    Participants receive 10 mM phosphate buffer without active AV-1980R, formulated with Advax-CpG55.2, by intramuscular injection at Weeks 0, 4, and 38.

    Other: Placebo

Interventions

  • BiologicalAV-1980R 20 µg

    AV-1980R is an investigational recombinant protein tau vaccine based on the MultiTEP platform. Participants receive 20 µg of AV-1980R formulated with Advax-CpG55.2, consisting of Advax and CpG55.2, by intramuscular injection at Weeks 0, 4, and 38.

  • BiologicalAV-1980R 60 µg

    AV-1980R is an investigational recombinant protein tau vaccine based on the MultiTEP platform. Participants receive 60 µg of AV-1980R formulated with Advax-CpG55.2, consisting of Advax and CpG55.2, by intramuscular injection at Weeks 0, 4, and 38.

  • BiologicalAV-1980R 180 µg

    AV-1980R is an investigational recombinant protein tau vaccine based on the MultiTEP platform. Participants receive 180 µg of AV-1980R formulated with Advax-CpG55.2, consisting of Advax and CpG55.2, by intramuscular injection at Weeks 0, 4, and 38.

  • OtherPlacebo

    The placebo consists of 10 mM phosphate buffer without active AV-1980R, formulated with Advax-CpG55.2, consisting of Advax and CpG55.2. It is administered by intramuscular injection at Weeks 0, 4, and 38.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events and Serious Adverse Events

    Number of participants who experience one or more treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs), summarized by severity and relationship to study intervention.

    Time frame: Baseline through Week 58

Secondary outcomes

  1. Number of Participants with Clinically Significant Changes in Vital Signs

    Number of participants with clinically significant abnormalities or changes in blood pressure, heart rate, respiratory rate, or body temperature.

    Time frame: Baseline through Week 58

  2. Number of Participants with Clinically Significant Changes in ECG Results

    Number of participants with new or worsening clinically significant ECG abnormalities.

    Time frame: Baseline through Week 58

  3. Number of Participants with Clinically Significant Changes in Laboratory Tests

    Number of participants with new or worsening abnormalities in hematology, serum chemistry, coagulation, or urinalysis results.

    Time frame: Baseline through Week 58

  4. Number of Participants with Clinically Significant Changes in Physical Examinations

    Number of participants with new or worsening abnormal findings on physical examination.

    Time frame: Screening through Week 58

  5. Number of Participants with Clinically Significant Changes in Neurological Examinations

    Number of participants with new or worsening abnormal neurological findings.

    Time frame: Screening through Week 58

  6. Number of Participants with New MRI Abnormalities, Including ARIA-E and ARIA-H

    Number of participants with new MRI findings of vasogenic edema or sulcal effusion (ARIA-E), cerebral microhemorrhage, macrohemorrhage, or superficial siderosis (ARIA-H), or new ischemic findings.

    Time frame: Screening and Weeks 6, 40, and 58

  7. Change from Baseline in Columbia-Suicide Severity Rating Scale Assessment

    Change from baseline in suicidal ideation and behavior assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS).

    Time frame: Baseline and Weeks 38, 40, 50, and 58

  8. Change from Baseline in Serum Anti-Tau Antibody Titers

    Serum anti-tau antibody titers measured using a validated enzyme-linked immunosorbent assay.

    Time frame: Baseline through Week 58

  9. Change from Baseline in MultiTEP-Specific T-Helper Cell Responses

    MultiTEP-specific interferon-gamma-producing T-helper cells detected in peripheral blood mononuclear cells using an ELISPOT assay after stimulation with MultiTEP T-helper peptides.

    Time frame: Baseline through Week 58

  10. Change from Baseline in Tau-Specific Autoreactive T-Helper Cell Responses

    Tau-specific interferon-gamma-producing T-helper cells detected in peripheral blood mononuclear cells using an ELISPOT assay after stimulation with the Tau2-18 peptide.

    Time frame: Baseline through Week 58

Other outcomes

  1. Change from Baseline in Plasma Alzheimer's Disease Biomarker Concentrations

    Change from baseline in plasma concentrations of Aβ42, Aβ40, p-tau217, p-tau181, p-tau231, total tau, neurofilament light chain, and glial fibrillary acidic protein.

    Time frame: Baseline through Week 58

  2. Change from Baseline in Serum Immunoglobulin Isotypes and IgG Subclasses

    Change from baseline in serum levels of IgM, total IgG, and IgG subclasses IgG1, IgG2, IgG3, and IgG4.

    Time frame: Baseline through Week 58

  3. Change from Baseline in Activated T-Cell Subsets

    Change from baseline in activated T-cell subsets in peripheral blood mononuclear cells, assessed by flow cytometry.

    Time frame: Baseline through Week 58

  4. Change from Baseline in T-Cell Proliferative Response

    Change from baseline in the proliferative response of T cells following antigen stimulation, assessed by flow cytometry.

    Time frame: Baseline through Week 58

  5. Change from Baseline in Polarization of Cellular Immune Responses

    Change from baseline in cytokine production by activated T cells in peripheral blood mononuclear cells.

    Time frame: Baseline through Week 58

  6. Change from Baseline in Plasma Biomarker Ratios

    Change from baseline in the plasma Aβ42/Aβ40 ratio and p-tau217/Aβ1-42 ratio.

    Time frame: Baseline through Week 58

  7. Change from Screening in Brain Tau Tangle Burden on PET

    Change in brain tau tangle burden assessed using \[18F\]MK-6240 positron emission tomography.

    Time frame: Screening and Week 58

  8. Change from Screening in Mini-Mental State Examination Score

    Change from screening in cognitive function measured using the Mini-Mental State Examination.

    Time frame: Screening and Week 58

  9. Change from Screening in Clinical Dementia Rating Global Score

    Change from screening in cognitive and functional status measured using the Clinical Dementia Rating global score.

    Time frame: Screening and Week 58

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2029, 35 months after the start.

Of 73 non-industry phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 35 months is below that.

Counting every sponsor, half of 236 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 8, 2025
StartActual
Jun 23, 2026
Primary completionEst.
Jun 15, 2029
CompletionEst.
Oct 15, 2029
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07158905
Lead sponsor
Institute for Molecular Medicine
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Jun 23, 2026
Primary completion
Jun 15, 2029 (estimated)
Completion
Oct 15, 2029 (estimated)
Last update
Aug 21, 2026

Study contacts

Roman Kniazev
Contact
rkniazev@immed.org
7145963981
Anahit Ghochikyan
Contact
aghochikyan@immed.org
7145963981
Michael Agadjanyan, PhD
principal investigator · Institute MM
Roman Kniazev
study director · Institute MM

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion